



EUROPEAN
HEMATOLOGY
ASSOCIATION



Ferrata Storti
Foundation

Haematologica 2017
Volume 102(10):1758-1766

Exome sequencing identifies recurrent *BCOR* alterations and the absence of *KLF2*, *TNFAIP3* and *MYD88* mutations in splenic diffuse red pulp small B-cell lymphoma

Laurent Jallades,^{1,2} Lucile Baseggio,^{1,2} Pierre Sujobert,^{1,2,3} Sarah Huet,^{1,2,3} Kaddour Chabane,^{1,2} Evelyne Callet-Bauchu,^{1,2,3} Aurélie Verney,^{2,3} Sandrine Hayette,^{1,2} Jean-Pierre Desvignes,^{4,5} David Salgado,^{4,5} Nicolas Levy,^{4,5,6} Christophe Bérout,^{4,5,6} Pascale Felman,^{1,2} Françoise Berger,^{2,3,7} Jean-Pierre Magaud,^{1,2,3} Laurent Genestier,² Gilles Salles^{2,3,8} and Alexandra Traverse-Glehen^{2,3,7}

¹Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'Hématologie, Pierre-Bénite; ²Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team "Clinical and Experimental Models of Lymphomagenesis", Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oullins; ³Université Claude Bernard Lyon-1; ⁴Aix-Marseille Université, GMGF, 13385, Marseillee; ⁵INSERM, UMR_S 910, 13385, Marseille; ⁶APHM, Hôpital TIMONE Enfants, Laboratoire de Génétique Moléculaire, 13385, Marseille; ⁷Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'Anatomie Pathologique, Pierre-Bénite and ⁸Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre-Bénite, France

ABSTRACT

Splenic diffuse red pulp lymphoma is an indolent small B-cell lymphoma recognized as a provisional entity in the World Health Organization 2008 classification. Its precise relationship to other related splenic B-cell lymphomas with frequent leukemic involvement or other lymphoproliferative disorders remains undetermined. We performed whole-exome sequencing to explore the genetic landscape of ten cases of splenic diffuse red pulp lymphoma using paired tumor and normal samples. A selection of 109 somatic mutations was then evaluated in a cohort including 42 samples of splenic diffuse red pulp lymphoma and compared to those identified in 46 samples of splenic marginal zone lymphoma and eight samples of hairy-cell leukemia. Recurrent mutations or losses in *BCOR* (the gene encoding the BCL6 corepressor) – frameshift (n=3), nonsense (n=2), splicing site (n=1), and copy number loss (n=4) – were identified in 10/42 samples of splenic diffuse red pulp lymphoma (24%), whereas only one frameshift mutation was identified in 46 cases of splenic marginal zone lymphoma (2%). Inversely, *KLF2*, *TNFAIP3* and *MYD88*, common mutations in splenic marginal zone lymphoma, were rare (one *KLF2* mutant in 42 samples; 2%) or absent (*TNFAIP3* and *MYD88*) in splenic diffuse red pulp lymphoma. These findings define an original genetic profile of splenic diffuse red pulp lymphoma and suggest that the mechanisms of pathogenesis of this lymphoma are distinct from those of splenic marginal zone lymphoma and hairy-cell leukemia.

Correspondence:

gilles.salles@chu-lyon.fr

Received: November 24, 2016.

Accepted: July 12, 2017.

Pre-published: July 27, 2017.

doi:10.3324/haematol.2016.160192

Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/102/10/1758

©2017 Ferrata Storti Foundation

Material published in *Haematologica* is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>.

Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>,

sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.



Introduction

Splenic diffuse red pulp lymphoma (SDRPL) with circulating villous lymphocytes is a rare indolent B-cell lymphoma involving the spleen, bone marrow and peripheral blood and is characterized by various clinical, morphological and immunological features.¹⁻³ However, SDRPL was defined as a provisional entity in the World Health Organization 2008 classification and in its recent release in 2016, and assigned to the unclassifiable splenic B-cell lymphomas/leukemias.^{4,5} Indeed, SDRPL

may present some overlapping features with other splenic B-cell lymphomas or small B-cell leukemias such as splenic marginal zone lymphoma (SMZL), hairy cell leukemia (HCL) and, especially, its variant form (HCL-v). The differential diagnosis may be difficult because of the absence of pathognomonic diagnostic markers. Recurrent mutations have been reported in HCL (*BRAF* V600E), HCL-v (*MAP2K1*) and in SMZL (*KLF2*, *NOTCH2*), indicating characteristic mutational patterns and distinctive oncogenic pathways in each of these entities.⁶⁻¹⁵ Some mutations in *NOTCH1*, *NOTCH2*, *MYD88*, *TP53*, *MAP2K1*, and *CCND3* have recently been described in SDRPL, though the studies were non-exhaustive and lacked detailed comparisons with other B-cell malignancies.¹⁴⁻¹⁶ In the present study, we explored the genetic landscape of SDRPL using whole-exome sequencing of paired tumor and normal samples. We confirmed and extended our findings through the targeted sequencing of 109 mutations in a validation series of SDRPL and compared these data with those obtained for SMZL and HCL.

Methods

Case selection

Diagnoses of HCL, SDRPL and SMZL were established by histological analyses of spleen (62 cases) or peripheral blood (38 cases) (Table 1). Given the frequent policy of watchful waiting and the low rate of splenectomy in SDRPL patients, 31 samples were included in the study after a diagnostic procedure based on thorough cytological examination of peripheral blood smears completed with bone marrow analyses, extensive flow cytometry immunophenotyping, and cytogenetic analyses. The immunophenotypic characteristics of SDRPL were previously shown to discriminate this type of lymphoma from other lymphoid malignancies.^{2,3} In our experience, SDRPL can be clearly distinguished from SMZL using a scoring system based on five membrane markers (CD11c, CD22, CD76, CD27 and CD38) and from HCL given that SDRPL does not co-express typical HCL markers such as CD25, CD103 and CD123.² However, in some cases, a partial expression of CD103 may be observed in SDRPL. The criteria used to recognize each entity were in accordance with the World Health Organization 2008 classification, completed with recent published updates.^{2,17-23} The clinico-pathological characteristics of the HCL, SDRPL and SMZL series are detailed in Table 1. Informed consent to participation in this study was obtained from patients, and the procedures were conducted in accordance with the Helsinki Declaration and the Biological Resource Center policy of the Hospices Civils de Lyon. Furthermore, the institutional review board of the Hospices Civils de Lyon approved the research protocol (DC-2015-2566).

Whole-exome sequencing

Whole-exome sequencing was performed on a discovery cohort (flowchart in *Online Supplementary Figure S1*), which included ten cases of SDRPL (namely, SDRPL #1, 3, 5, 7, 8, 9, 10, 12, 13, and 15). DNA from tumor cells was obtained from seven frozen spleen samples and three positively immunoselected villous lymphoma B-cell (CD19⁺) samples isolated from peripheral blood (to verify the origin of the samples, see Figure 1). Paired DNA from non-malignant cells was purified from spleen fibroblasts obtained after culture of the original tissue biopsy or from the non-B-cell fraction obtained after immunoselection using a human anti-CD19 antibody-conjugated magnetic microbead kit according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach,

Germany). The purity of the B-cell fractions was determined by flow cytometry and systematically exceeded 90%. Non-B-cell fractions contained less than 5% CD20⁺ cells.

Genomic DNA was enriched in protein-coding sequences using the in-solution exome capture SureSelect Human All Exon 50-Mb kit (Agilent Technologies) according to the manufacturer's protocol. The captured targets were subjected to sequencing using the Illumina HiSeq2000 analyzer (Illumina) with the paired-end 2 x 75 bp read option. Exome capture, massively parallel sequencing and quality controls were performed at IntegraGen (Evry, France). Paired-end reads obtained by high-throughput sequencing were aligned with the human genome reference hg19/NCBI GRCh37, and differences from the reference sequence were identified separately for tumor and normal samples using the CASAVA pipeline (Illumina) (IntegraGen), as well as another pipeline based on BWA-MEM, SAMBAMBA, and GATK (INSERM UMR S910, Marseille, France). Merge analysis, data mining and manual review were performed using VarAFT (<http://varaft.eu>) and ALAMUT software (Interactive Biosoftware, Rouen, France). To investigate genomic copy number aberrations (e.g., copy number gains and copy number losses), we used the Bioconductor DNACopy package (DNACopy 1.32.0), comparing the DNA exome data with the paired reference sample data and used the circular binary segmentation algorithm to segment DNA copy number data. All changes

Table 1. Clinico-pathological comparison between the HCL, SDRPL and SMZL cases of our series

	HCL	SDRPL	SMZL
Total samples (n=96)	8	42	46
Spleen	3	11	46
Peripheral blood	5	31	0
Sex ratio (F:M)	2:6 (0.33)	15:27 (0.56)	*25:21 (1.19)
Median age (years)	47	80	*68
Immunophenotype ^a			
κ:λ ratio	4:3 (1.33)	14:28 (0.50)	*24:17 (1.41)
CD11c	7/7 (100%)	35/41 (85%)	*14/26 (54%)
CD25	7/7 (100%)	0/41 (0%)	0/26 (0%)
CD27	0/6 (0%)	8/33 (24%)	*32/35 (91%)
CD103	6/6 (100%)	9/40 (23%)	*0/27 (0%)
CD123	6/6 (100%)	0/31 (0%)	1/19 (5%)
CD76	4/4 (100%)	20/23 (87%)	*2/13 (15%)
CD38	1/7 (14%)	2/40 (5%)	*15/39 (39%)
CD23	0/7 (0%)	2/42 (5%)	*19/41 (46%)
ANXA1	3/3 (100%)	0/11 (0%)	0/46 (0%)
Cytogenetic	n.a.	24/42 (57%)	41/46 (89%)
Deletion 7q	-	6/24 (25%)	13/41 (32%)
Trisomy 3	-	1/24 (4%)	*9/41 (22%)
Trisomy 12	-	3/24 (13%)	*9/41 (22%)
Trisomy 18	-	1/24 (4%)	*4/41 (10%)
Complex karyotype	-	3/24 (13%)	*13/41 (32%)
IGHV gene status	4/8	36/42 (86%)	40/46 (87%)
IGHV mutated (<100%) ^a	4/4	32/36 (89%)	36/40 (90%)
IGHV1-2	0/4	1/36 (3%)	*15/40 (38%)
IGHV3-23	0/4	5/36 (14%)	*1/40 (3%)
IGHV3-30	1/4	2/36 (6%)	1/40 (3%)
IGHV4-34	1/4	8/36 (22%)	*3/40 (8%)
IGHV4-59	0/4	4/36 (11%)	5/40 (13%)

Marker (*) indicates feature that discriminates between SDRPL and SMZL entities. ^aAll antigen expressions were studied by flow cytometry except CD76, which was assessed by immunocytochemistry. ^bPercentage of IGHV mutated cases considering a case 'mutated' when it had ≤ 100% of homology with the germline sequence. n.a.: not available.




Figure 1. Distribution of mutations in hairy-cell leukemia, splenic diffuse red pulp lymphoma and splenic marginal zone lymphoma. Each column represents a type of lymphoma and corresponding tissue (HCL: hairy cell lymphoma; SDRPL: splenic diffuse red pulp lymphoma; SMZL: splenic marginal zone lymphoma; PB: peripheral blood; SP: spleen; B+: CD19+ immunoselected sample). The orange colored boxes indicate the ten cases investigated by whole-exome sequencing. Six of them were also reanalyzed by targeted sequencing as internal controls, whereas the four remaining were not (NR; not resequenced). Each row (top) represents a gene linked to the corresponding RAS/MAPK, NF-κB or NOTCH signaling pathway. Three types of mutations (missense, nonsense, frameshift/indel) are highlighted in different colors. Details of the mutations are available in *Online Supplementary Table S3*. Gene copy number (CN) was only reported as a gain (↑) or loss (↓) for relevant genes (*), namely *BCOR* and *TNFAIP3*. The last row (bottom) represents the IGHV gene status, homology with germline sequence percentage, and cytogenetic findings (complex karyotype, trisomy 3, 12, 18 and deletion 7q) for each case when available.

were compared to the catalogue of the Database of Genomic Variants to provide a comprehensive summary of structural variations in the human genome.

Targeted gene sequencing

A panel of 109 genes was selected from the exploratory exome data for subsequent analyses; these genes were selected according to their previous description in mutational landscape studies of other B-cell malignancies, to their well-established role in B-cell physiology or to the type of mutation they produce (predicted to be deleterious or damaging according to SIFT and PolyPhen2-score). The genes, exon positions and coverage are listed in *Online Supplementary Table S2*. High-throughput sequencing was performed on a validation series of 38 SDRPL samples, consisting of six samples from the discovery cohort used as positive controls (namely, SDRPL #1, 3, 5, 8, 9 and 12) and 32 new SDRPL samples, as well as 46 SMZL and eight HCL samples. The origin of the samples is shown in Figure 1. DNA was extracted from frozen spleen samples, from CD19⁺ immunoselected cells, or from non-immunoselected peripheral blood mononuclear cells after Ficoll-isolation using patients' samples with a total lymphocyte count exceeding $5 \times 10^9/L$ (mean $14 \times 10^9/L$; minimum: $5.8 \times 10^9/L$; maximum: $92 \times 10^9/L$). All of the spleen tissue samples were infiltrated with over 70% B-cell lymphoma tumor cells.

Library preparation, capture, sequencing, variant detection, and annotation were performed by IntegraGen. Exons of genomic DNA samples were captured using the Agilent in-solution enrichment methodology with the biotinylated oligonucleotide probe library, followed by paired-end 75-bp massively parallel sequencing on an Illumina HiSeq2000. Image analysis and base calling were performed using the Illumina Real Time Analysis Pipeline version 1.14 and default parameters. Bioinformatics analysis of the sequencing data was based on the Illumina pipeline (CASA-VA1.8.2). Only positions included in the bait coordinates were conserved. Genetic variation annotation was performed using the IntegraGen in-house pipeline, which consists of gene annotation (RefSeq) and detection of known polymorphisms (dbSNP 132, 1000Genome) followed by characterization of the mutations (exonic, intronic, silent, nonsense, etc.). For each position, exomic frequencies were determined using the IntegraGen Exome database, and exome results were provided by HapMap.

The procedure for detecting copy number variation was adapted from previously published methods; read depths of each exon from all of the target genes were obtained for each sample using DeCovA.^{24,25} Exon read depths (ERD) were then normalized against the sum of all ERD from the same sample. A copy number ratio (CNR) was obtained by dividing the ERD of the sample by the median ERD of all of the samples as a control: $CNR_x = (ERD_x / \sum ERD_{1>n})_{sample} / (ERD_x / \sum ERD_{1>n})_{control}$. For the two genes located on chromosome Xp (*BCOR* and *KDM6A*), a 2-fold extrapolation was applied to the normalized ERD for males. Copy number ratios <0.7 and >1.25 were considered to represent a loss and gain, respectively. Chromosomal abnormalities (chromosome X loss or gain) were confirmed by copy number variation detection by whole-exome sequencing using a circular binary segmentation algorithm and compared to that of the paired reference genome or karyotype analysis when available.

Microarray-based comparative genomic hybridization

A 60K oligonucleotide microarray (Agilent Technologies) was used according to the manufacturer's instructions to confirm the microdeletion of the *BCOR* locus, identified by the detection, by whole-exome sequencing, of copy number variation (SDRPL case: VL_218).

Results

Whole-exome sequencing of the discovery cohort of SDRPL resulted in the identification of more than 300 unique somatic mutations among the ten different tumor samples (*Online Supplementary Table S1*). These included exon missense (83%), frameshift (5%), nonsense (4%), untranslated regions (5%), and intron splicing site (3%) alterations. Some of the mutated genes were previously associated with various other malignancies. These mutated genes encode proteins in various pathways, including cell cycle regulation (*CCND3*, *MGA*, *MYC*), epigenetic regulation (*BCOR*, *EZH1*, *HIST1H1D*, *HIST1H2AD*, *HIST4H4*, *KAT6A*, *KDM6A*, *NCOA6*), the RAS-MAPK pathway (*HRAS*, *KIF26A*, *NRAS*, *RAF1*, *WNK1*), NF- κ B signaling (*IKBKB*, *TBK1*, *TRAF3*), NOTCH signaling (*NOTCH1*, *NOTCH2*, *DTX3L*, *DTX1*, *SPEN*), and cytoskeleton and cell-matrix interactions (*ARHGAP20*, *ARHGEF15*, *ARHGEF17*, *ROCK1*, *MYLK*, *DOCK6*, *DNAH5*, *DNAH7*, *DNAI1*, *RAPGEF2*, *RFTN1*, *DSP*, *DTNB*). In the SDRPL discovery cohort, we detected only three recurrently mutated genes [*CCND3* (cyclin D3), *HIST4H4* (histone cluster 4, H4), and *RFTN1* (raftlin, lipid raft linker 1)] in two of the ten SDRPL samples (*Online Supplementary Table S1*).

Given the characteristic mutational profiles previously identified in other B-cell malignancies and after extensive manual review and data mining of the SDRPL discovery cohort, we selected a panel of 109 target genes the functions of which may be relevant during lymphomagenesis and the types of mutations of which were predicted by the SIFT and PolyPhen2-score to be deleterious or damaging (*Online Supplementary Table S2*). This panel was used to further explore the validation cohort, including SDRPL, SMZL and HCL samples, by high-throughput sequencing and to assess the frequency of mutations in each of these lymphoma/leukemia entities. All of the mutations detected by whole-exome sequencing were confirmed by targeted gene sequencing for SDRPL cases, sequenced using both methodologies. All of the samples of the validation cohort, except one, displayed at least one of the 109 target gene mutations, with the number of mutations ranging from 1-13 in some samples. Only a few recurrent and discriminative mutations were identified and are described hereafter, with a promising candidate being mutations or losses in *BCOR* since these affected 10/42 SDRPL patients compared to 1/46 patients with SMZL and 0/8 of those with HCL (Figure 1).

Recurrent *BCOR* mutations and deletions in splenic diffuse red pulp lymphoma

A single mutation in a splicing site of *BCOR* was initially detected in the discovery cohort and was confirmed to be somatic (Figure 1 and *Online Supplementary Table S3*). This mutation was identified in the same splicing site position as another mutation reported in the COSMIC database as being COSM521431. Additional *BCOR* mutations were identified in five SDRPL cases of the validation set. These mutations were distributed along the gene (Figure 2) with in exons 4, 5 and 11 (*BCOR* gene coverage: 100%; mean depth analysis: 345 reads). These mutations were characterized by splicing site (1/6), nonsense (2/6) and frameshift (3/6) alterations. The mutations exhibited a high variant allele frequency, with the exception of two frameshift mutations that exhibited a lower variant allele frequency.

The tumor cell content was elevated in these two cases, which also harbored some mutations in other genes with a higher variant allele frequency, possibly indicating a sub-clonal change (*Online Supplementary Table S3*). Finally, the pattern of these mutations strongly suggests that they would result in loss of function of *BCOR*.

Since such loss of function may arise from the deletion of *BCOR* on chromosome Xp11.4, we further analyzed our data to look for copy number variations. A single *BCOR* allele is supposed to be functional in both males (one copy on the single chromosome X) and females (because of X-inactivation). Copy number losses of the *BCOR* locus were identified by analysis of exon read depths in four SDRPL female patients displaying no *BCOR* mutation within the single remaining allele (Figure 3A). Three of these losses involved the whole chromosome X, whereas the last deletion was a microdeletion of approximately 669 kb assessed by microarray-comparative genomic hybridization [arr[GRCh37] Xp11.4(39576746_40245183)x1], only targeting an uncharacterized long non-coding RNA (LOC101927476) and the *BCOR* gene (Figure 3B). Two copy number gains of the *BCOR* locus were also observed in two SDRPL cases. In one male patient, who also had a *BCOR* frameshift mutation, the copy number gain explained the observed variant allele frequency of

40% in that individual (VL#208) (Figures 1 and 3A, *Online Supplementary Table S3*). Some of these abnormalities were confirmed by copy number variation detection from whole-exome sequencing or by karyotype analysis when available (Figure 3). Taken together, these findings demonstrated an alteration in *BCOR* in 11/42 SDRPL cases, most of them (10/11) being potentially pathogenic (mutations or loss). Furthermore, the percentage of *BCOR* alterations in cases with spleen histology (2/11 cases, 18%) was similar to that of the cases without spleen histology (8/31, 26%).

A single *BCOR* frameshift mutation (distinct from the previous ones identified in SDRPL samples) was detected in the 46 SMZL samples (2%) (Figure 1 and *Online Supplementary Table S3*). Three copy number variations of the *BCOR* locus were also observed in three SMZL patients, and in all three cases entailed a gain. No *BCOR* alteration (mutation, gain or deletion) was observed in the eight HCL samples.

MAP2K1 and BRAF mutations

While no *MAP2K1* (MEK1) mutation was detected in the SMZL samples (Figure 1), three mutated cases were observed in SDRPL samples (3/42; 7%). Two mutations (*MAP2K1* p.I103N and p.C121S) were previously reported in HCL-v.⁷ Of the three patients with *MAP2K1* mutations




Figure 2. *BCOR* mutations in splenic diffuse red pulp lymphoma, lymphoid and hematologic malignancies. The distribution of mutations along the *BCOR* sequence was drawn using cBioPortal (<http://www.cbioportal.org>). Mutation diagram circles are colored with respect to the corresponding mutation types. Six distinct mutations were detected in our SDRPL series (top), compared to mutations reported in lymphoid (middle) or hematologic (bottom) malignancies.^{43,44} *BCOR*: BCL-6 corepressor, non-ankyrin-repeat region (1202 - 1414); *Ank_2*: Ankyrin repeats (3 copies) (1467 - 1560); *PUF3*: BCORL-PCGF1-binding domain (1634 - 1747).




Figure 3. Copy number evaluation at the *BCOR* Xp11.4 locus in hairy-cell leukemia, splenic diffuse red pulp lymphoma and splenic marginal zone lymphoma. (A) Copy number (CN) variation was detected from exon sequencing of the target genes after normalization using DeCovA.^{25,24} Each row represents a lymphoma case (HCL: hairy-cell lymphoma; SDRPL: splenic diffuse red pulp lymphoma; SMZL: splenic marginal zone lymphoma). Each column represents an exon of two different genes (*BCOR* and *KDM6A*) located at locus Xp11.4. A progressive gradation of CN variation distinguishes loss (red) and gain (green). Right: mean copy number ratio of the *BCOR* locus, with some references in brackets corresponding to the next inserts (B-G). (B) Microarray-based comparative genomic hybridization confirmed a monoallelic microdeletion of approximately 669 kb (arr[GRCCh37] Xp11.4(39576746_40245183)x1), encompassing the *BCOR* locus (SDRPL female patient VL_218), whereas the *KDM6A* gene was unaffected. (C-D) Copy number variation of chromosome X detected by whole-exome sequencing using a circular binary segmentation algorithm and compared to a paired reference genome (log₂ ratio). These two female patients with SDRPL acquired complete monosomy X. (E-G) Detailed karyotype results confirmed monosomy X (E), tetrasomy X (F) or trisomy X (G).

in our series, two also harbored a *BCOR* mutation (VL#201, VL#208). In contrast to HCL-v cases with *MAP2K1* mutations, these two SDRPL cases did not use the IGHV4-34 gene, as indicated in *Online Supplementary Table S3* (comments column).

Whereas *BRAF* p.V600E is the hallmark of HCL, we identified one distinct *BRAF* mutation (p.G469A) in 1/42 SDRPL samples (2%). This case was characterized by an unmutated immunoglobulin IGHV4-34 sequence and a non-HCL immunological profile (CD25⁺/CD103⁺/CD123⁺) and harbored both *BRAF* p.G469A and *MAP2K1* p.I103N mutations but no *BCOR* mutation.

A single sample of the 46 SMZL (2%) cases harbored both a *BRAF* p.V600E mutation and a frameshift mutation of *KLF2* (MZ#104). The diagnosis of SMZL was confirmed after further review of the spleen histology in this patient, who also had a typical IGHV1-2*04 rearrangement and trisomy 3q.

***KLF2*, *TNFAIP3* and *MYD88* mutations**

Mutations in *KLF2*, *TNFAIP3* and *MYD88*, which are known to activate the NF- κ B pathway, were observed in 14/46 (30%), 9/46 (20%) and 4/46 (9%) of SMZL patients, respectively (Figure 1 and *Online Supplementary Table S3*).^{4,8,11,26} *TNFAIP3* and *MYD88* mutations were not detected in either SDRPL or HCL samples.

Only one *KLF2* mutant (1/42; 2%) was observed in an SDRPL patient. The diagnosis of SDRPL in this case was based on cytological features of a peripheral blood smear with more than 60% villous lymphoma cells among the lymphoid cells, an immunological SDRPL score of 0/5 (dimCD11c⁺/dimCD22⁺/CD38⁺/CD27⁺/CD76⁺) and the fact that IGHV3-23 usage is more frequently observed in SDRPL than SMZL.² One other *KLF2* mutation was detected in a HCL sample, which also displayed a *BRAF* V600E mutation.

Other mutations found in both splenic diffuse red pulp lymphoma and splenic marginal zone lymphoma

Finally, different mutations (already reported in other B-cell malignancies) likely implicated in the activation of the Notch pathway (i.e., mutations in *NOTCH2*, *NOTCH1*, and *SPEN*) were identified in 7/42 SDRPL (17%) and 14/46 SMZL (30%) samples (Figure 1 and *Online Supplementary Table S3*).^{6,8,9}

Other mutations were recurrently observed but were distributed across both SDRPL and SMZL samples, in particular *CCND3* [in 9 (21%) of 42 SDRPL and 6 (13%) of 46 SMZL samples], *BIRC3*, *TP53*, *MYC* and *CXCR4*. No additional recurrent mutations were observed in *HIST4H4* and *RFTN1*, previously identified in two cases of the SDRPL discovery cohort. These findings show that, in addition to the original somatic mutation pattern described above, SDRPL can also share some mutations with its closest B-cell malignancy.

Discussion

We explored the mutational landscape of SDRPL with circulating villous lymphocytes in an attempt to identify diagnostic pathognomonic markers associated with this rare unclassifiable (World Health Organization 2016 classification) splenic B-cell lymphoma. One of the limitations of our study was the restricted number of patients having

undergone histological spleen analyses, and we thus partially relied on stringent immunophenotypic and cytological criteria to select SDRPL cases from peripheral blood samples. This methodology is consistent with the current medical management of patients suffering from splenic lymphoma, who are preferentially administered rituximab rather than being submitted to splenectomy. However, irrespective of the origin of the SDRPL tissues analyzed, their genetic landscape was clearly distinct from the SMZL and HCL samples used herein as comparative B-cell malignancy cases. Indeed, we identified recurrent *BCOR* mutations or losses in 10/42 SDRPL cases (24%), while these remained rare in SMZL (1/46) and absent in HCL (0/8). Most *BCOR* mutations (identified in 6 cases), as well as *BCOR* deletions (in 4 cases including a microdeletion), were speculated to result in inactivation of gene function. These mutations were not reported in the COSMIC database, except for one case with a *BCOR* p.S340Vfs*41 mutation similar to the reported pS340* mutation (COSM5945498). There were no particular associations between *BCOR* alterations and cytogenetic features, IGHV gene usage, or the mutational pattern of SDRPL cases.

Germline *BCOR* mutations have been detected in patients with inherited oculofaciocardiodental and Lenz microphthalmia syndromes.²⁷ Recently, massively parallel sequencing has identified inactivating somatic *BCOR* mutations at a very low frequency in patients with various types of solid neoplasia but also in patients with hematologic malignancies, such as acute myeloid leukemia, myelodysplastic syndrome, T-cell prolymphocytic leukemia, and extranodal NK/T-cell lymphoma, nasal type.²⁸⁻³⁶ Altogether, these data underline the critical role of *BCOR* in cell differentiation and oncogenesis.

BCOR was first identified as a corepressor whose product interacts specifically with BCL6.^{37,38} Through epigenetic modifications, the enzymatic activity of the BCOR complex provides a mechanism for silencing BCL6 targets. Although BCOR and BCL6 play key roles in germinal center formation, and BCL6 alterations are involved in the transformation of germinal center B cells, their functions in other B cells remain elusive.^{39,40} The predicted inactivating mutations of *BCOR* or acquired hemizygoty observed in SDRPL may lead to the loss of BCL6 repression, but BCL6 expression is not usually detected by immunohistochemistry in SDRPL. Recent data also indicate that BCL6/BCOR inhibits Notch-activated target genes during embryonic development.⁴⁰ Given the frequency of mutations of genes involved in the Notch pathway in SDRPL (17%), it would be interesting to investigate whether *BCOR* loss-of-function might represent an alternative mechanism for activating this pathway in B cells. Overall, how *BCOR* mutations or deletions might participate in SDRPL oncogenesis remains unknown.

Recently, recurrent *CCND3* mutations have been described in six of 25 (24%) of another series of SDRPL cases.¹⁶ In our series, we also observed recurrent *CCND3* mutations in nine of 42 SDRPL cases (21%), but *CCND3* mutations were also detected in six of 46 SMZL cases (13%). Case selection based on diagnostics, obtained either following spleen histology or through morphological and immunological examination of peripheral blood, may potentially account for these distinct findings. Further studies are, therefore, required to identify the spectrum of *CCND3* mutations among splenic lymphomas more precisely. A nonsense mutation in *CDKN1B*, the gene that

encodes the cyclin-dependent kinase inhibitor and that interacts with cyclin D3, was found in another case of SDRPL.¹⁶ The immunohistochemical expression of CCND3 showed a selective expression of cyclin D3 by most neoplastic cells in SDRPL spleen tissues. Considering that cyclin D3 works downstream of BCL6 in germinal center development, it could be hypothesized that dysregulation of the BCL6/BCOR complex on the one hand or CCND3 dysregulation on the other hand may represent two aspects of the same pathophysiology in SDRPL; this remains to be explored more thoroughly.⁴¹

Some *MAP2K1* mutations were also reported in the present series of SDRPL cases but at a low frequency (7%). In contrast, a high prevalence (48%) of *MAP2K1* mutations was previously reported in HCL-v and IGHV4-34-expressing HCL, suggesting a possible degree of overlap between HCL-v and SDRPL.⁷ Among the 12 lymphoma samples in the present series sharing the IGHV4-34 pattern (8 SDRPL, 3 SMZL and 1 HCL that was *BRAF* V600E-positive), we identified only one case of IGHV4-34 in a SDRPL patient with a *MAP2K1* mutation, also harboring a *BRAF* G469A mutation (VL#203), but lacking the *BCOR* mutation. These previously unknown molecular findings may result in tools for the diagnosis of an atypical form of HCL rather than a true case of SDRPL. The two other *MAP2K1* mutants were identified in samples with distinct IGHV rearrangements that also harbored a *BCOR* mutation, which was the most frequent abnormality in our SDRPL series. Further screening of *BCOR* mutations in the

HCL-v series may, therefore, refine our understanding of the relationship between HCL-v and SDRPL.

Finally, the frequent *BCOR* mutations and the absence of alterations in genes regulating the NF- κ B pathway (triple-negative for *KLF2*, *TNFAIP3* and *MYD88* mutations) or the absence of a *BRAF* mutation appear to delineate a specific genetic pattern of SDRPL, which is distinct from that already identified in SMZL, HCL or HCL-v. Exploration of these mutational patterns should improve the differential diagnosis of splenic B-cell lymphoma/leukemia and other lymphoproliferative disorders, in combination with morphological and immunological criteria currently used for their diagnosis. This will be essential for pursuing the biological and clinical characterization of this range of B-cell lymphoproliferative disorders. Our findings also pave the way for additional functional studies to characterize the oncogenic mechanism by which *BCOR* may promote lymphomagenesis and how this may potentially lead to the development of novel therapeutics.

Acknowledgments

We acknowledge Prof Damien Sanlaville, Dr Nicolas Chatron, Audrey Labalme and Jessica Michel for assistance with the microarray-CGH experiment and the Centre de Ressources Biologiques Sudbiothèque of the Hospices Civils de Lyon. We thank Dr Brigitte Manship for improving the use of English in the manuscript and for her critical reading.

Funding

References

1. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? *Blood*. 2008;111(4):2253-2260.
2. Baseggio L, Traverse-Glehen A, Callet-Bauchu E, et al. Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). *Hematol Oncol*. 2011;29(1):47-51.
3. Miguet L, Lennon S, Baseggio L, et al. Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas. *Leukemia*. 2013;27(8):1748-1750.
4. Piris MA, Foucar K, Mollejo M, Campo E, Falini B. Splenic B-cell lymphoma/leukaemia unclassifiable. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. IARC Press Lyon. 2008;191-193.
5. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390.
6. Tiacci E, Trifonov V, Schiavoni G, et al. *BRAF* mutations in hairy-cell leukemia. *N Engl J Med*. 2011;364(24):2305-2315.
7. Waterfall JJ, Arons E, Walker RL, et al. High prevalence of *MAP2K1* mutations in variant and IGHV4-34-expressing hairy-cell leukemias. *Nat Genet*. 2013;46(1):8-10.
8. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of *NOTCH2* and other pathways regulating marginal zone development. *J Exp Med*. 2012;209(9):1537-1551.
9. Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic *NOTCH2* mutations in splenic marginal zone lymphoma. *J Exp Med*. 2012;209(9):1553-1565.
10. Martínez N, Almaraz C, Vaqué JP, et al. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. *Leukemia*. 2013;28(6):1334-1340.
11. Clipson A, Wang M, de Leval L, et al. *KLF2* mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. *Leukemia*. 2014;29(5):1177-1185.
12. Piva R, Deaglio S, Fama R, et al. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. *Leukemia*. 2014;29(2):503-507.
13. Parry M, Rose-Zerilli MJ, Ljungstrom V, et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. *Clin Cancer Res*. 2015;21(18):4174-4183.
14. Martínez D, Navarro A, Martínez-Trillos A, et al. *NOTCH1*, *TP53*, and *MAP2K1* mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease. *Am J Surg Pathol* 2015;40(2):192-201.
15. Traverse-Glehen A, Verney A, Gazzo S, et al. Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies. *Leuk Lymphoma*. 2016;58(3):666-675.
16. Curiel-Olmo S, Mondejar R, Almaraz C, et al. Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent *CCND3* mutations. *Blood*. 2017;129(8):1042-1045.
17. Traverse-Glehen A, Baseggio L, Callet-Bauchu E, et al. Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity? *Br J Haematol*. 2010;150(1):113-116.
18. Traverse-Glehen A, Baseggio L, Salles G, Felman P, Berger F. Splenic marginal zone B-cell lymphoma. *Curr Opin Oncol*. 2011;23(5):441-448.
19. Traverse-Glehen A, Baseggio L, Salles G, Coiffier B, Felman P, Berger F. Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. *Discov Med*. 2012;13(71):253-265.
20. Wotherspoon AC. Extranodal and splenic small B-cell lymphoma. *Mod Pathol*. 2013;26:S29-S41.
21. Kanellis G, Mollejo M, Montes-Moreno S, et al. Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. *Haematologica*. 2010;95(7):1122-1129.
22. Baseggio L, Traverse-Glehen A, Petinataud F, et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. *Haematologica*. 2010;95(4):604-612.
23. Ponzoni M, Kanellis G, Pouliou E, et al. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma. *Am J Surg Pathol*. 2012;36(11):1609-1618.
24. Pasmant E, Parfait B, Luscan A, et al. Neurofibromatosis type 1 molecular diag-

- nosis: what can NGS do for you when you have a large gene with loss of function mutations? *Eur J Hum Genet.* 2014;23(5):596-601.
25. Dimassi S, Simonet T, Labalme A, et al. Comparison of two next-generation sequencing kits for diagnosis of epileptic disorders with a user-friendly tool for displaying gene coverage, DeCovA. *Appl Transl Genom.* 2015;7:19-25.
 26. Rossi D, Deaglio S, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. *Blood.* 2011;118(18):4930-4934.
 27. Ng D, Thakker N, Corcoran CM, et al. Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR. *Nat Genet.* 2004;36(4):411-416.
 28. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature.* 2012;488(7409):106-110.
 29. Yamamoto Y, Abe A, Emi N. Clarifying the impact of polycomb complex component disruption in human cancers. *Mol Cancer Res.* 2014;12(4):479-484.
 30. Moreira AL, Won HH, McMillan R, et al. Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis. *J Thorac Oncol.* 2015;10(2):373-380.
 31. Abe H, Kaneda A, Fukayama M. Epstein-Barr virus-associated gastric carcinoma: use of host cell machineries and somatic gene mutations. *Pathobiology.* 2015;82(5):212-223.
 32. Grossmann V, Tiacci E, Holmes AB, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood.* 2011;118(23):6153-6163.
 33. Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. *Blood.* 2013;122(18):3169-3177.
 34. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. *N Eng J Med.* 2015;373(1):35-47.
 35. Stengel A, Kern W, Zenger M, et al. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker. *Genes Chromosomes Cancer.* 2016;55(1):82-94.
 36. Lee S, Park HY, Kang SY, et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. *Oncotarget.* 2015;6(19):17764-17776.
 37. Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. *Gen Dev.* 2000;14(14):1810-1823.
 38. Hatzl K, Melnick A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. *Trends Mol Med.* 2014;20(6):343-352.
 39. Polo JM, Dell'Oso T, Ranuncolo SM, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. *Nat Med.* 2004;10(12):1329-1335.
 40. Sakano D, Kato A, Parikh N, et al. BCL6 canalizes notch-dependent transcription, excluding mastermind-like1 from selected target genes during left-right patterning. *Dev Cell.* 2010;18(3):450-462.
 41. Cato MH, Chintalapati SK, Yau IW, Omori SA, Rickert RC. Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. *Mol Cell Biol.* 2010;31(1):127-137.
 42. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal.* 2013;6(269):p11-p11.
 43. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012;2(5):401-404.